NZ510631A - Esters of (+)-alpha-(2,3- dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5HT2A receptor antagonist MDL 100,907 - Google Patents

Esters of (+)-alpha-(2,3- dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5HT2A receptor antagonist MDL 100,907

Info

Publication number
NZ510631A
NZ510631A NZ510631A NZ51063198A NZ510631A NZ 510631 A NZ510631 A NZ 510631A NZ 510631 A NZ510631 A NZ 510631A NZ 51063198 A NZ51063198 A NZ 51063198A NZ 510631 A NZ510631 A NZ 510631A
Authority
NZ
New Zealand
Prior art keywords
compound
pharmaceutically acceptable
patient
medicament
fluorophenyl
Prior art date
Application number
NZ510631A
Other languages
English (en)
Inventor
Albert A Carr
Hijfte Luc E Van
Raymond W Kosley
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of NZ510631A publication Critical patent/NZ510631A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ510631A 1998-10-14 1998-10-14 Esters of (+)-alpha-(2,3- dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5HT2A receptor antagonist MDL 100,907 NZ510631A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/021608 WO2000021930A1 (fr) 1998-10-14 1998-10-14 Esters de (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol et leur utilisation comme promedicament de l'antagoniste du recepteur 5ht2a mdl 110,907

Publications (1)

Publication Number Publication Date
NZ510631A true NZ510631A (en) 2003-07-25

Family

ID=22268079

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ510631A NZ510631A (en) 1998-10-14 1998-10-14 Esters of (+)-alpha-(2,3- dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5HT2A receptor antagonist MDL 100,907

Country Status (21)

Country Link
EP (1) EP1121345A1 (fr)
JP (1) JP2002527422A (fr)
KR (1) KR100515429B1 (fr)
CN (1) CN1160333C (fr)
AU (1) AU1083099A (fr)
BR (1) BR9816049A (fr)
CA (1) CA2347469C (fr)
CZ (1) CZ20011331A3 (fr)
EA (1) EA003667B1 (fr)
EE (1) EE200100219A (fr)
HK (1) HK1039332A1 (fr)
HR (1) HRP20010278A2 (fr)
HU (1) HUP0200517A3 (fr)
IL (2) IL142479A0 (fr)
NO (1) NO320417B1 (fr)
NZ (1) NZ510631A (fr)
PL (1) PL193306B1 (fr)
SK (1) SK5082001A3 (fr)
TR (1) TR200101047T2 (fr)
UA (1) UA57859C2 (fr)
WO (1) WO2000021930A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099076A1 (en) * 2000-05-25 2002-07-25 Richard Scheyer D. Use of (+)-a-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
CN102241667B (zh) * 2010-05-14 2013-10-23 中国人民解放军军事医学科学院毒物药物研究所 1-[(4-羟基哌啶-4基)甲基]吡啶-2(1h)-酮衍生物及其制备方法和用途
CN106892897A (zh) * 2015-12-21 2017-06-27 上海科胜药物研发有限公司 一种羟哌吡酮游离碱新晶型及其制备方法
CN106928187A (zh) * 2015-12-31 2017-07-07 上海奥博生物医药技术有限公司 一种盐酸羟哌吡酮新晶型及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU652759B2 (en) * 1990-06-01 1994-09-08 Aventisub Ii Inc. (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol

Also Published As

Publication number Publication date
UA57859C2 (uk) 2003-07-15
HUP0200517A3 (en) 2002-12-28
CN1160333C (zh) 2004-08-04
EA003667B1 (ru) 2003-08-28
EA200100361A1 (ru) 2001-10-22
NO20011805L (no) 2001-06-08
CA2347469A1 (fr) 2000-04-20
SK5082001A3 (en) 2001-11-06
PL347318A1 (en) 2002-03-25
CN1314887A (zh) 2001-09-26
AU1083099A (en) 2000-05-01
IL142479A0 (en) 2002-03-10
EE200100219A (et) 2002-08-15
PL193306B1 (pl) 2007-01-31
EP1121345A1 (fr) 2001-08-08
NO20011805D0 (no) 2001-04-09
HRP20010278A2 (en) 2002-06-30
HK1039332A1 (en) 2002-04-19
HUP0200517A2 (en) 2002-06-29
JP2002527422A (ja) 2002-08-27
KR100515429B1 (ko) 2005-09-20
KR20010106517A (ko) 2001-11-29
IL142479A (en) 2006-06-11
NO320417B1 (no) 2005-12-05
CZ20011331A3 (cs) 2001-08-15
CA2347469C (fr) 2006-02-28
WO2000021930A1 (fr) 2000-04-20
TR200101047T2 (tr) 2001-08-21
BR9816049A (pt) 2001-07-03

Similar Documents

Publication Publication Date Title
US6063793A (en) Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidi nemethanol
CA2410554C (fr) Utilisation de (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4piperidinemethanol ou ses promedicaments dans le traitement de patients pour des symptomes de demenceet de psychose provoquee par la dopamine
AU2001264842A1 (en) Use of (+)-alpha -(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4- piperidinemerthanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
AU704435B2 (en) Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl) ethyl)-4-piperidinemethanol in treating depressive disorders and bipolar disorders
CA2347469C (fr) Esters de (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol et leur utilisation comme promedicament de l'antagoniste du recepteur 5ht2a mdl 100,907
AU2004200993A1 (en) Esters of (+)-alpha-(2,3-dimethoxyphenyl-[2-(4-flurophenyl) ethyl]-4-piperidinemethanol and their use as prodrugs of the 5HT2a receptor antagonist MDL 110,907
BG65206B1 (bg) Естери на (+)-алфа-(2,3-диметоксифенил)-1-[2-(4-флуорoфенил)етил]-4- пиперидинметанол, метод за тяхното получаване и приложението им като предшественици на 5ht2a рецепторния антагонист mdl 110,907
MXPA01003535A (en) Esters of (+)-alpha-( 2,3- dimethoxyphenyl) -1-[2-(4- fluorophenyl) ethyl]-4- piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907
TW461885B (en) Esters of (+)-Α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol
JP5060133B2 (ja) エステル誘導体及びその医薬用途
PL203533B1 (pl) Zastosowanie (+)- a-(2,3-dimetoksyfenylo)-1-[2-(4-fluorofenylo)etylo]-4-piperydynometanolu lub jego proleku

Legal Events

Date Code Title Description
PSEA Patent sealed
S35A Application for proceedings under section 35 (restoration of lapsed patents)
RENW Renewal (renewal fees accepted)
S35R Proceedings under section 35 (restoration of lapsed patents): patent restored